Prediction of the Oncotype DX recurrence score: Use of pathology-generated equations derived by linear regression analysis

Modern Pathology

Volumn 26, Issue 5, 2013, Pages 658-664

  Klein, Molly E ^a   Dabbs, David J ^b   Shuai, Yongli ^c   Brufsky, Adam M ^b   Jankowitz, Rachel ^b   Puhalla, Shannon L ^b   Bhargava, Rohit ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

breast cancer; ER PR HER2 Ki 67; immunohistochemistry; morphology; Oncotype DX recurrence score prediction

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER RISK; DIAGNOSTIC KIT; HEALTH; HUMAN; IMMUNOHISTOLOGY; LINEAR REGRESSION ANALYSIS; MAGEE EQUATION; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM;

EID: 84877016055     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.36     Document Type: Article

References (29)

1. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27:219-226.
2. Pinder SE, Ellis IO, Elston CW. Prognostic factors in primary breast carcinoma. J Clin Pathol 1995;48: 981-983.
3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
4. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995; 71:146-149.
5. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
6. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
7. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008;21:1255-1261.
8. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109:716-721.
9. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
10. Dabbs DJ, Klein ME, Mohsin SK, et al. High falsenegative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 2011;29:4279-4285.
11. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-4278.
12. Gwin K, Pinto M, Tavassoli FA. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score. Int J Surg Pathol 2009;17:303-310.
13. Sahebjam S, Aloyz R, Pilavdzic D, et al. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer 2011;105:1342-1345.
14. Acs G, Esposito NN, Kiluk J, et al. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX recurrence scores in low-grade invasive breast carcinomas. Mod Pathol 2012;25:556-566.
15. Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007;53:1084-1091.
16. Bergers E, Jannink I, van Diest PI, et al. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum Pathol 1997;28:95-100.
17. De Cecco L, Musella V, Veneroni S, et al. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer 2009;9:409.
18. Donhuijsen K, Schmidt U, Hirche H, et al. Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol 1990;21:709-714.
19. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 2012;25:1098-1105.
20. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-219.
21. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144.
22. Ravdin PM. A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients. Bull Cancer 1995;82(Suppl 5):561s-564s.
23. Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 1996;23:43-50.
24. Allison KH, Kandalaft PL, Sitlani CM, et al. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 2012;131:413-424.
25. Geradts J, Bean SM, Bentley RC, et al. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010;28:969-977.
26. Lee JJ, Shen J. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers? Am Surg 2011;77:1364-1367.
27. Tang P, Wang J, Hicks DG, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest 2010;28:978-982.
28. Clark BZ, Dabbs DJ, Cooper KL, et al. Impact of progesterone receptor semiquantitative immunohistochemical result on oncotype DX recurrence score: a quality assurance study of 1074 Cases. Appl Immunohistochem Mol Morphol 2012; PMID: 23060300; e-pub ahead of print.
29. Tang G, Cuzick J, Costantino JP, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 2011;29:4365-4372.